Use of cyclosporine, infliximab, and anti-IL17 agents may be associated with increased risk of symptomatic urinary tract infection in women with psoriasis.
A clinical guideline for the use of phototherapy for the care and management of adult patients with psoriasis developed by the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) has been published.
Findings indicated by perivascular fat attenuation index, as measured by coronary CT angiography.
Type, rather than number, of comorbidities, has a greater effect on the quality of life of patients with psoriatic arthritis, according to recent research.
41, 39.5 percent use alternative, complementary therapies; higher use seen with severe psoriasis.
High waist circumference, regardless of overall body mass index, tied to higher risk.
Time to onset found to be 2 to 3 months for anxiety disorders and other conditions.
Addition of apremilast to a regimen of topical corticosteroids was safe and effective in patients with moderate plaque-type psoriasis.
A fixed-dose combination lotion comprised of halobetasol propionate 0.01% and tazarotene 0.045% (HP/TAZ) is more effective for treating moderate-to-severe plaque psoriasis than either component alone.
Researchers completed 2 post hoc analyses of large, double-blind trials examining the efficacy of HP/TAZ combination therapy for clinically meaningful outcomes.
The extracutaneous manifestations of psoriasis and guidance on use of biologic treatment for management of psoriasis are discussed in 2 new guidelines.
In patients with hypertension, psoriasis linked to increased risk for cardiovascular procedures, surgeries.
DLQI-R allows more patients to achieve threshold for becoming candidates for biologic treatment.
Psoriasis appears to be significantly associated with inflammatory bowel disease.
Most studies evaluated fish oil, acupuncture, indigo naturalis, curcumin, meditation.
The final analysis set comprised biologic-naïve individuals — individuals who had filled an initial prescription for etanercept, infliximab, adalimumab, or ustekinumab after 2 years without using any biologic agent during the study period.
Some of the comorbidities include increased lipid levels, hypertension, and diabetes.
Medication-related adverse events occur more frequently with methotrexate in children with moderate to severe psoriasis.
Patients with psoriasis whose disease affects >10% of their body surface area (BSA) are at an increased risk for death compared with the general population.
Sleep complaints among individuals with psoriasis warrant greater clinical attention, as they have a greater chance for developing obstructive sleep apnea.